Jacek Olczak, Philip Morris CEO (Yen Meng Jiin/Singapore Press via AP Images)
Kicking the habit, Philip Morris forges $1.5B deal to acquire Vectura in race to build a top inhaled-drug company
Philip Morris is switching focus from smoking to health in a big way. And today it’s trumpeting a move into inhaled therapeutics with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
